Hamblin Peter S, Russell Anthony W, Talic Stella, Zoungas Sophia
School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia; Department of Endocrinology and Diabetes, Alfred Health, Melbourne, VIC, Australia; Department of Endocrinology and Diabetes, Western Health, St Albans, VIC, Australia.
School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia; Department of Endocrinology and Diabetes, Alfred Health, Melbourne, VIC, Australia.
Trends Endocrinol Metab. 2025 Jan 3. doi: 10.1016/j.tem.2024.12.006.
With the rising prevalence of type 2 diabetes mellitus (T2DM) and obesity, several previously under-recognised complications associated with T2DM are becoming more evident. The most common of these emerging complications are metabolic dysfunction-associated steatotic liver disease (MASLD), cancer, dementia, sarcopenia, and frailty, as well as other conditions involving the lung, heart, and intestinal tract. Likely causative factors are chronic inflammation and insulin resistance, whereas blood glucose levels appear to play a lesser role. We discuss these complications and the new approaches being developed to prevent and manage them, especially incretin-based therapies. We argue that these new interventions may work in a complementary way to other proven cardiorenal protective therapies to reduce the burden of T2DM complications.
随着2型糖尿病(T2DM)和肥胖症患病率的上升,几种先前未被充分认识的与T2DM相关的并发症正变得愈发明显。这些新出现的并发症中最常见的是代谢功能障碍相关脂肪性肝病(MASLD)、癌症、痴呆、肌肉减少症和衰弱,以及其他涉及肺部、心脏和肠道的病症。可能的致病因素是慢性炎症和胰岛素抵抗,而血糖水平似乎起的作用较小。我们讨论了这些并发症以及正在开发的预防和管理它们的新方法,特别是基于肠促胰岛素的疗法。我们认为,这些新干预措施可能与其他已证实的心脏肾脏保护疗法以互补的方式发挥作用,以减轻T2DM并发症的负担。